StockData

Cellectis vs Century Therapeutics

CLLS and IPSC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLLS and IPSC compare

Century Therapeutics scores higher on the StockData Score (8 against 3 for Cellectis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLLSIPSC
Size and price
Market cap–$297M
Share price$1.04$1.64
Change, 1 year−70.9%253%
Change, 5 years−88.0%−90.5%
Beta (5Y)2.471.96
Employees22978
StockData Score
Total score38 (better)
Valuation score01 (better)
Growth score2 (better)1
Performance score11
Health score05 (better)
Dividend score00
Valuation
P/B–1.3×
FCF yield–−29.7%
Growth
Revenue growth (TTM)75.8%–
Revenue growth, 5Y average7.4%–
Profitability
Gross margin100%–
Operating margin−45.3%–
Net margin−92.7%–
FCF margin−57.2%–
Return on equity−97.8%−49.7% (better)
Return on invested capital−122%−113% (better)
Financial health
Debt / equity–0.00
Interest coverage−0.6×–
Current ratio–8.28
Altman Z-score–−1.76
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield–−0.20%
Shareholder yield–−0.20%
Ownership
Held by institutions9.4%87.3%
Held by insiders53.4%3.8%
Insider net buying, 12 months–$10.6K
Short interest, % of float–18.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.